Evidence map›Paper›PMID 41840212›Full record

ArticleCellular and molecular life sciences : CMLS2026

Identification of alterations of immunometabolism associated with Pompe disease.

Helena Costa-Verdera, Marco Gargaro, Umut Cagin, Giorgia Manni, Giulia Scalisi, Philippe Veron, Estevão Carlos Silva Barcelos, Benedetta Pieroni, Giulia Mencarelli, Doriana Ricciuti and 8 more

Abstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Helena Costa-Verdera *UPMC, Sorbonne Universités, Paris, France.
Marco Gargaro *Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.
Umut CaginGenethon, 91000, Evry, France.
Giorgia ManniDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.
Giulia ScalisiDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.
Philippe VeronGenethon, 91000, Evry, France.
Estevão Carlos Silva BarcelosDepartment of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.
Benedetta PieroniDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.
Giulia MencarelliDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.
Doriana RicciutiDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.
Ivan NemazanyyPlatform for Metabolic Analyses, Necker Federative Research Structure, INSERM US24/CNRS UMS3633, Paris, France.
Peggy SanatineGenethon, 91000, Evry, France.
Laetitia van WittenbergheGenethon, 91000, Evry, France.
Pascal LaforêtRaymond Poincaré Teaching Hospital, APHP, Garches, France.
David-Alexandre GrossGenethon, 91000, Evry, France.
Giuseppe RonzittiGenethon, 91000, Evry, France.
Francesca FallarinoDepartment of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.
Federico MingozziUPMC, Sorbonne Universités, Paris, France. federico@navatx.com.ORCID http://orcid.org/0009-0002-9658-6466

Funding

Associazione Italiana per la Ricerca sul Cancro 30318European Research Council 101078646Fondazione Telethon GMR22T1081
6 · The paper itself

Abstract

Pompe disease (PD) is a neuromuscular lysosomal storage disorder caused by mutations in the GAA gene, characterized by progressive glycogen accumulation in multiple tissues and autophagy and metabolic abnormalities. While immunological changes have largely been overlooked as part of PD's symptomatology, autophagy and metabolic regulation are crucial in immune cell function. High incidence of immune reactions against therapeutic recombinant GAA (rhGAA) in PD patients suppose an important hindrance to treatment efficacy, yet the impact of GAA deficiency on the immune system remains unclear. Here we explored the T cell phenotype in late-onset PD patient cells and in a PD mouse model, revealing heightened expression of activation markers in effector T cells compared to controls. Additionally, we observed decreased frequencies of regulatory T cells in mice. We also hypothesized that metabolic and autophagy defects in PD extend to immune cells. In fact, Gaa−/− T cells reproduced autophagy and mitophagy defects reported in muscle cells, and upon stimulation, T cells showed impaired mitochondrial function consistent with defective mitophagy. Preliminary findings also suggest that alterations translate to a subset of CD24+CD172− conventional dendritic cells with regulatory function, which could indirectly contribute to higher T cell activation. Our observations indicate that immune homeostasis is altered in PD, offering new insights on immune dysfunction in the context of lysosomal impairment and providing the rationale for investigating its potential role in the pathogenesis of PD.

Indexed as

Glycogen Storage Disease Type IIalpha-GlucosidasesAnimalsAutophagyDendritic CellsDisease Models, AnimalHumansLymphocyte ActivationMiceMice, KnockoutMitochondriaMitophagyT-LymphocytesT-Lymphocytes, Regulatoryalpha-GlucosidasesAutophagyEnzyme replacement therapyImmunogenicityImmunometabolismMitophagyT cells

Identifiers

PMID41840212
PMCPMC13048873

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.